menu

Cancer Gene Therapy Market

Schedule Call

Cancer Gene Therapy Market

Cancer Gene Therapy Market by Therapy Type (Gene-Induced Immunotherapy, Gene Transfer), Indication (Lung Cancer, Prostate Cancer), End-user (Academic & Research Institutes, Biopharmaceutical Companies) - Global Outlook & Forecast 2023-2031

GR - 958175 Category: Pharmaceuticals

Number of pages: 100  |  Report Format: PDF  |  Published date: March 17, 2023

Historical Years – 2021  |  Base Year – 2022  |  Forecasted Years – 2023-2031


Cancer Gene Therapy Market Scope

Report Attribute

Details

Market Size Value in 2022

US$ 1.64 billion

Revenue forecast in 2031

US$ 8.33 billion

CAGR

19.8%

Base Year for Estimation

2022

Forecast Period

2023-2031

Historical Year

2021

Segments Covered

Therapy Type, Indication, End-user, and Region

Regional Scope

North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa

Report Overview

According to the deep-dive market assessment study by Growth Plus Reports, the global cancer gene therapy market was valued at US$ 1.64 billion in 2022 and is expected to register a revenue CAGR of 19.8% to reach US$ 8.33 billion by 2031.

Cancer Gene Therapy Market Fundamentals

Cancer gene therapy is a type of treatment that involves modifying or manipulating genes to treat or prevent cancer. Cancer gene therapy aims to correct genetic mutations that lead to cancer or target cancer cells directly with therapeutic genes. Several different types of gene therapy can be used to treat cancer. One approach involves introducing new genes into cancer cells that either destroy the cancer cells or prevent them from growing and spreading. Another approach involves modifying a patient’s immune cells so that they can recognize and attack cancer cells.

Some types of cancer gene therapy are still experimental and not widely available. Others are already being used in clinical practice. For instance, CAR T-cell therapy is a type of cancer gene therapy that has shown promising results in treating certain types of leukemia and lymphoma. Lung cancer, pancreatic cancer, prostate cancer, and malignant melanoma have all seen promising outcomes in recent clinical trials of second and third-generation vaccines. Gene therapy is a new treatment option with great promise, especially for metastatic cancers. It is oncolytic virotherapy, which uses viral particles that replicate inside the cancer cell to kill it. While cancer gene therapy holds great promise as a potential cure, it is still a relatively new field, and many challenges need to be overcome before it can become a routine part of cancer treatment.

[56765]

Cancer Gene Therapy Market Dynamics

The increasing incidence of cancer and growing demand for gene therapy globally are responsible for the revenue growth of the global cancer gene therapy market. Globally, there were 17.0 million new instances of cancer and 9.5 million cancer-related deaths in 2018, according to estimates from the International Agency for Research on Cancer. By 2040, the global burden is expected to grow to 27.5 million new cancer cases and 16.3 million cancer deaths simply due to the revenue growth and aging of the population. Conventional gene treatments now target the immune system to improve remissions for patients with advanced-stage tumors due to the rising role of immunotherapy in cancer treatment. For instance, the Hadassah Cancer Research Institute, Jerusalem, announced in September 2022 that it would serve as the Cancer RNA’s leader. Cancer RNA is a global forum devoted to creating and using RNA-based immunotherapy to exploit anti-cancer immune responses efficiently.

Advancements in gene therapy technologies are responsible for the revenue growth of the global cancer gene therapy market. Over the years, there have been significant advancements in gene therapy technologies, which have led to the development of more efficient and effective gene therapies. For instance, in March 2021, the U.S. FDA approved Abecma (idecabtagene vicleucel), a cell-based gene therapy, to treat patients with multiple myeloma who could not respond to the initial lines of therapy.

The growing investment in gene therapy research is also driving the global market. This has led to the development of several promising gene therapies, which are expected to drive the revenue growth of the cancer gene therapy market. For instance, in August 2022, the FDA approved Bluebird Bio’s BLUE.O gene therapy to treat patients with rare conditions requiring routine blood transfusions. Additionally, the increased government funding around the world is providing financial support for gene therapy research, further driving the revenue growth of the global cancer gene therapy market.

However, gene therapy involves introducing genetic material into the patient’s cells, which carries potential risks, such as immune response, toxicity, and off-target effects. Safety concerns have been a major hurdle for the development of gene therapies, and clinical trials have been halted in the past due to adverse events. Gene therapy is a complex and expensive process that requires specialized equipment and expertise. The cost of developing and manufacturing gene therapies is high, resulting in high treatment costs for patients. This can limit the adoption of gene therapy, especially in countries with limited healthcare budgets.

Cancer Gene Therapy Market Ecosystem

The global cancer gene therapy market has been analyzed from four perspectives: therapy type, indication, end-user, and region.

Cancer Gene Therapy Market by Therapy Type

[74574]

Based on therapy type, the global cancer gene therapy market has been segmented into gene-induced immunotherapy, gene transfer, and oncolytic virotherapy.

The gene-induced immunotherapy segment accounted for the largest revenue share of the global cancer gene therapy market. The dominance of this segment can be attributed to research studies aiming to lower the proliferation of various types of cancer by strengthening the immune system. Many gene therapies for cancers are designed based on immunotherapy factors. For instance, PROVENGE (by Dendreon Corporation) is an autologous cellular immunotherapy designed to stimulate a subject’s immune system against prostate cancer.

The oncolytic virotherapy segment is projected to grow at the fastest revenue CAGR in the forecast period. This is attributed to the favorable outcomes and the level of efficacy offered by oncolytic virotherapy. By activating natural killer cells, oncolytic viruses can kill cancer cells without harming nearby healthy cells. Furthermore, oncolytic virotherapy research is eligible for generous awards. For instance, the National Institutes of Health awarded the researchers at the Center for Nuclear Receptors and Cell Signaling at the University of Houston a US$ 1.8 million grant in July 2022 to study oncolytic virotherapy.

Cancer Gene Therapy Market by Indication

Based on indication, the global cancer gene therapy market has been segmented into lung cancer, prostate cancer, breast cancer, pancreatic cancer, and others.

 The breast cancer segment is a rapidly growing segment in the market. According to a WHO report from 2021, breast cancer is the type of cancer that affects people the most worldwide. Given that breast cancer is characterized by several genetic alterations, gene therapy is best suited to treat it. Using viruses that selectively proliferate and eradicate cancer cells has the potential to treat a variety of conditions. Oncolytic viruses can be created to deliver a transgene in addition to their ability to be cytotoxic and have a tropism for cancer cells. The HF10 clone with reduced virulence was created through genetic modification of the herpes simplex virus-1 (HSV-1). Mice treated with HF10 survived up to 120 days, more than 40 days longer than control mice after intratumoral injection, in early preclinical experiments with the MM102-TC breast cancer tumors in vivo.

Cancer Gene Therapy Market by End User

Based on end-user, the global cancer gene therapy market has been segmented into academic & research institutes, biopharmaceutical companies, and others. 

The biopharmaceutical companies segment accounted for the largest revenue share of the global cancer gene therapy market. This is attributed to the increasing global incidence of several malignancies owing to diverse inherited, environmental, and lifestyle risk factors. Additionally, the market is driven by the rising acceptance of elemental gene therapy choices by biopharmaceutical giants to develop cancer therapeutic regimes. Many novel therapeutic medications are going through various stages of testing, and businesses are working hard to commercialize them in various parts of the world. For instance, in January 2020, Bluebird Bio, Inc. offered its medicine, ZYNTEGLO, in Germany as a one-time gene therapy option for patients aged 12 years and above.

Cancer Gene Therapy Market by Region 

Based on region, the global cancer gene therapy market has been segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.

North America accounts for the largest revenue share in the global cancer gene therapy market. Gene therapies for various cancers are being developed and made available for purchase. The market is primarily driven by factors including the increasing incidence of cancer, the growing demand for cutting-edge cancer treatments, and the rising expenditures on R&D. Also, the market in the region is growing due to the presence of major market players, their research into developing gene therapy for the treatment of cancer, and cooperative efforts to advance research. For instance, Merck & Co., Inc. and Orna Therapeutics Inc. cooperated in August 2022 to explore, develop, and commercialize several programs, including the usage of mRNA for cancer gene therapy.

The Europe cancer gene therapy market is one of the largest and fastest-growing markets globally. The European Union has a vast network of research centers, universities, and companies actively involved in developing gene therapies for various types of cancers. Germany, France, the U.K., and Switzerland are some of the major players in the Europe cancer gene therapy market. In recent years, the Europe cancer gene therapy market has witnessed significant revenue growth, driven by increased research funding, a rise in clinical trials, and advancements in gene editing technologies. As new gene treatments obtain regulatory approval and hit the market in the upcoming years, the market is anticipated to maintain its revenue growth trajectory. Also, the European Union’s Horizon Europe Mission on Cancer was launched in September 2021 to provide money for various programs focused on lowering the prevalence of cancer in Europe through fostering research and innovation in cancer therapies. The initiative is anticipated to help more than 3 million cancer survivors by 2030.

Cancer Gene Therapy Market Competitive Landscape

The prominent players operating in the global cancer gene therapy market are:

  • GlaxoSmithKline Inc.
  • Merck & Co., Inc.
  • GenVec
  • Introgen Therapeutics Inc.
  • Altor Bioscience Inc.
  • BioCancell Therapeutic Inc.
  • Bluebird bio-Inc.
  • Bristol-Myers Squibb Company
  • Abeona Therapeutics Inc.
  • Asklepios BioPharmaceutical Inc.

Cancer Gene Therapy Market Strategic Developments

  • In March 2023, three internally produced investigational preclinical gene therapy product candidates from Abeona Therapeutics Inc.’s ophthalmology division were disclosed. The usage of new adeno-associated virus capsids in treatments for severe hereditary eye illnesses is being studied by Abeona’s preclinical programs.
  • In February 2023, Akamis Bio, a clinical-stage oncology company, announced an extension of its current collaboration with the Parker Institute for Cancer Immunotherapy to include a clinical partnership with the Cancer Research Institute that would concentrate on developing cutting-edge therapies for pancreatic cancer.

Frequently Asked Questions About This Report

The global cancer gene therapy market is expected to grow at a revenue CAGR of 19.8% during the forecast period.

GlaxoSmithKline Inc., Merck & Co., Inc., GenVec, Introgen Therapeutics Inc., and Altor Bioscience Inc. are among the key players in the global cancer gene therapy market.

The breast cancer segment accounts for the largest revenue share in the global cancer gene therapy market.

Europe is expected to observe the highest revenue growth in the cancer gene therapy market during the forecast period.

The global cancer gene therapy market was valued at US$ 1.64 billion in 2022.

Table of Content

  1. INTRODUCTION
    1. Market Ecosystem
    2. Timeline Under Consideration
      1. Historical Years – 2021
      2. Base Year – 2022
      3. Forecast Years – 2023 to 2031
    3. Currency Used in the Report
  2. RESEARCH METHODOLOGY 
    1. Research Approach
    2. Data Collection Methodology
    3. Data Sources
      1. Secondary Sources 
      2. Primary Sources
    4. Market Estimation Approach
      1. Bottom Up
      2. Top Down 
    5. Market Forecasting Model
    6. Limitations and Assumptions
  3. PREMIUM INSIGHTS
    1. Current Market Trends (COVID-19 Perspective)
    2. Key Players & Competitive Positioning (2022)
    3. Regulatory Landscape
  4. MARKET DYNAMICS
    1. Drivers
    2. Restraints/Challenges
    3. Opportunities
  5. GLOBAL CANCER GENE THERAPY MARKET - ANALYSIS & FORECAST, BY THERAPY TYPE
    1. Gene-Induced Immunotherapy
    2. Gene Transfer
    3. Oncolytic Virotherapy
  6. GLOBAL CANCER GENE THERAPY MARKET - ANALYSIS & FORECAST, BY INDICATION
    1. Lung Cancer
    2. Prostate Cancer
    3. Breast Cancer
    4. Pancreatic Cancer
    5. Others
  7. GLOBAL CANCER GENE THERAPY MARKET - ANALYSIS & FORECAST, BY END-USER
    1. Academic & Research Institutes
    2. Biopharmaceutical Companies 
    3. Others
  8. GLOBAL CANCER GENE THERAPY MARKET - ANALYSIS & FORECAST, BY REGION
    1. North America Cancer Gene Therapy Market
      1. North America Cancer Gene Therapy Market, by Therapy Type
      2. North America Cancer Gene Therapy Market, by Indication 
      3. North America Cancer Gene Therapy Market, by End-user
      4. North America Cancer Gene Therapy Market, by Country
        1. U.S.
          1. U.S. Cancer Gene Therapy Market, by Therapy Type
          2. U.S. Cancer Gene Therapy Market, by Indication
          3. U.S. Cancer Gene Therapy Market, by End-user
        2. Canada
          1. Canada Cancer Gene Therapy Market, by Therapy Type
          2. Canada Cancer Gene Therapy Market, by Indication 
          3. Canada Cancer Gene Therapy Market, by End-user
    2. Europe Cancer Gene Therapy Market
      1. Europe Cancer Gene Therapy Market, by Therapy Type
      2. Europe Cancer Gene Therapy Market, by Indication 
      3. Europe Cancer Gene Therapy Market, by End-user
      4. Europe Cancer Gene Therapy Market, by Country/Region
        1. Germany
          1. Germany Cancer Gene Therapy Market, by Therapy Type
          2. Germany Cancer Gene Therapy Market, by Indication 
          3. Germany Cancer Gene Therapy Market, by End-user
        2. U.K.
          1. U.K. Cancer Gene Therapy Market, by Therapy Type
          2. U.K. Cancer Gene Therapy Market, by Indication 
          3. U.K. Cancer Gene Therapy Market, by End-user
        3. France
          1. France Cancer Gene Therapy Market, by Therapy Type
          2. France Cancer Gene Therapy Market, by Indication 
          3. France Cancer Gene Therapy Market, by End-user
        4. Spain
          1. Spain Cancer Gene Therapy Market, by Therapy Type
          2. Spain Cancer Gene Therapy Market, by Indication 
          3. Spain Cancer Gene Therapy Market, by End-user
        5. Italy
          1. Italy Cancer Gene Therapy Market, by Therapy Type
          2. Italy Cancer Gene Therapy Market, by Indication  
          3. Italy Cancer Gene Therapy Market, by End-user
        6. Rest of Europe 
          1. Rest of Europe Cancer Gene Therapy Market, by Therapy Type
          2. Rest of Europe Cancer Gene Therapy Market, by Indication 
          3. Rest of Europe Cancer Gene Therapy Market, by End-user
    3. Asia Pacific Cancer Gene Therapy Market
      1. Asia Pacific Cancer Gene Therapy Market, by Therapy Type
      2. Asia Pacific Cancer Gene Therapy Market, by Indication 
      3. Asia Pacific Cancer Gene Therapy Market, by End-user
      4. Asia Pacific Cancer Gene Therapy Market, by Country/Region
        1. China
          1. China Cancer Gene Therapy Market, by Therapy Type
          2. China Cancer Gene Therapy Market, by Indication 
          3. China Cancer Gene Therapy Market, by End-user
        2. Japan
          1. Japan Cancer Gene Therapy Market, by Therapy Type
          2. Japan Cancer Gene Therapy Market, by Indication 
          3. Japan Cancer Gene Therapy Market, by End-user
        3. India
          1. India Cancer Gene Therapy Market, by Therapy Type
          2. India Cancer Gene Therapy Market, by Indication 
          3. India Cancer Gene Therapy Market, by End-user
        4. South Korea
          1. South Korea Cancer Gene Therapy Market, by Therapy Type
          2. South Korea Cancer Gene Therapy Market, by Indication 
          3. South Korea Cancer Gene Therapy Market, by End-user
        5. Australia
          1. Australia Cancer Gene Therapy Market, by Therapy Type
          2. Australia Cancer Gene Therapy Market, by Indication 
          3. Australia Cancer Gene Therapy Market, by End-user
        6. Rest of Asia Pacific
          1. Rest of Asia Pacific Cancer Gene Therapy Market, by Therapy Type
          2. Rest of Asia Pacific Cancer Gene Therapy Market, by Indication 
          3. Rest of Asia Pacific Cancer Gene Therapy Market, by End-user
    4. Latin America Cancer Gene Therapy Market
      1. Latin America Cancer Gene Therapy Market, by Therapy Type
      2. Latin America Cancer Gene Therapy Market, by Indication 
      3. Latin America Cancer Gene Therapy Market, by End-user
      4. Latin America Cancer Gene Therapy Market, by Country
        1. Brazil 
          1. Brazil Cancer Gene Therapy Market, by Therapy Type
          2. Brazil Cancer Gene Therapy Market, by Indication 
          3. Brazil Cancer Gene Therapy Market, by End-user
        2. Mexico 
          1. Mexico Cancer Gene Therapy Market, by Therapy Type
          2. Mexico Cancer Gene Therapy Market, by Indication 
          3. Mexico Cancer Gene Therapy Market, by End-user
        3. Argentina 
          1. Argentina Cancer Gene Therapy Market, by Therapy Type
          2. Argentina Cancer Gene Therapy Market, by Indication 
          3. Argentina Cancer Gene Therapy Market, by End-user
        4. Rest of Latin America 
          1. Rest of Latin America Cancer Gene Therapy Market, by Therapy Type
          2. Rest of Latin America Cancer Gene Therapy Market, by Indication  
          3. Rest of Latin America Cancer Gene Therapy Market, by End-user
    5. Middle East & Africa Cancer Gene Therapy Market
      1. Middle East & Africa Cancer Gene Therapy Market, by Therapy Type
      2. Middle East & Africa Cancer Gene Therapy Market, by Indication 
      3. Middle East & Africa Cancer Gene Therapy Market, by End-user
      4. Middle East & Africa Cancer Gene Therapy Market, by Country
        1. GCC Countries
          1. GCC Countries Cancer Gene Therapy Market, by Therapy Type
          2. GCC Countries Cancer Gene Therapy Market, by Indication 
          3. GCC Countries Cancer Gene Therapy Market, by End-user
        2. South Africa
          1. South Africa Cancer Gene Therapy Market, by Therapy Type
          2. South Africa Cancer Gene Therapy Market, by Indication 
          3. South Africa Cancer Gene Therapy Market, by End-user
        3. Rest of Middle East & Africa
          1. Rest of Middle East & Africa Cancer Gene Therapy Market, by Therapy Type
          2. Rest of Middle East & Africa Cancer Gene Therapy Market, by Indication 
          3. Rest of Middle East & Africa Cancer Gene Therapy Market, by End-user
  9. COMPANY PROFILE
    1. GlaxoSmithKline Inc.
      1. Business Snapshot 
      2. Products Offered 
      3. Financial Details 
      4. Strategic Development
    2. Merck & Co., Inc.
    3. GenVec
    4. Introgen Therapeutics Inc.
    5. Altor Bioscience Inc.
    6. BioCancell Therapeutic Inc.
    7. Bluebird bio Inc.
    8. Bristol-Myers Squibb Company
    9. Abeona Therapeutics Inc.
    10. Asklepios BioPharmaceutical Inc.

*Insights on financial performance are subject to the availability of information in the public domain

List of Tables

 

  1. Global Cancer Gene Therapy Market, by Therapy Type, 2021-2031 (US$ Million)
  2. Global Cancer Gene Therapy Market, by Indication , 2021-2031 (US$ Million)
  3. Global Cancer Gene Therapy Market, by End-user, 2021-2031 (US$ Million)
  4. Global Cancer Gene Therapy Market, by Region, 2021-2031 (US$ Million) 
  5. North America Cancer Gene Therapy Market, by Therapy Type, 2021-2031 (US$ Million)
  6.  North America Cancer Gene Therapy Market, by Indication , 2021-2031 (US$ Million)
  7. North America Cancer Gene Therapy Market, by End-user, 2021-2031 (US$ Million)
  8. North America Cancer Gene Therapy Market, by Country, 2021-2031 (US$ Million) 
  9. U.S. Cancer Gene Therapy Market, by Therapy Type, 2021-2031 (US$ Million) 
  10. U.S. Cancer Gene Therapy Market, by Indication , 2021-2031 (US$ Million)
  11. U.S. Cancer Gene Therapy Market, by End-user, 2021-2031 (US$ Million)
  12. Canada Cancer Gene Therapy Market, by Therapy Type, 2021-2031 (US$ Million)
  13. Canada Cancer Gene Therapy Market, by Indication , 2021-2031 (US$ Million)
  14. Canada Cancer Gene Therapy Market, by End-user, 2021-2031 (US$ Million)
  15. Europe Cancer Gene Therapy Market, by Therapy Type, 2021-2031 (US$ Million) 
  16. Europe Cancer Gene Therapy Market, by Indication , 2021-2031 (US$ Million)
  17. Europe Cancer Gene Therapy Market, by End-user, 2021-2031 (US$ Million)
  18. Europe Cancer Gene Therapy Market, by Country/ Region, 2021-2031 (US$ Million) 
  19. Germany Cancer Gene Therapy Market, by Therapy Type, 2021-2031 (US$ Million) 
  20. Germany Cancer Gene Therapy Market, by Indication , 2021-2031 (US$ Million)
  21. Germany Cancer Gene Therapy Market, by End-user, 2021-2031 (US$ Million)
  22. U.K. Cancer Gene Therapy Market, by Therapy Type, 2021-2031 (US$ Million) 
  23. U.K. Cancer Gene Therapy Market, by Indication , 2021-2031 (US$ Million)
  24. U.K. Cancer Gene Therapy Market, by End-user, 2021-2031 (US$ Million)
  25. France Cancer Gene Therapy Market, by Therapy Type, 2021-2031 (US$ Million) 
  26. France Cancer Gene Therapy Market, by Indication , 2021-2031 (US$ Million)
  27. France Cancer Gene Therapy Market, by End-user, 2021-2031 (US$ Million)
  28. Italy Cancer Gene Therapy Market, by Therapy Type, 2021-2031 (US$ Million) 
  29. Italy Cancer Gene Therapy Market, by Indication , 2021-2031 (US$ Million)
  30. Italy Cancer Gene Therapy Market, by End-user, 2021-2031 (US$ Million)
  31. Spain Cancer Gene Therapy Market, by Therapy Type, 2021-2031 (US$ Million) 
  32. Spain Cancer Gene Therapy Market, by Indication , 2021-2031 (US$ Million)
  33. Spain Cancer Gene Therapy Market, by End-user, 2021-2031 (US$ Million)
  34. Rest of Europe Cancer Gene Therapy Market, by Therapy Type, 2021-2031 (US$ Million) 
  35. Rest of Europe Cancer Gene Therapy Market, by Indication , 2021-2031 (US$ Million)
  36. Rest of Europe Cancer Gene Therapy Market, by End-user, 2021-2031 (US$ Million)
  37. Asia Pacific Cancer Gene Therapy Market, by Therapy Type, 2021-2031 (US$ Million) 
  38. Asia Pacific Cancer Gene Therapy Market, by Indication , 2021-2031 (US$ Million)
  39. Asia Pacific Cancer Gene Therapy Market, by End-user, 2021-2031 (US$ Million)
  40. Asia Pacific Cancer Gene Therapy Market, by Country/ Region, 2021-2031 (US$ Million) 
  41. China Cancer Gene Therapy Market, by Therapy Type, 2021-2031 (US$ Million)
  42. China Cancer Gene Therapy Market, by Indication , 2021-2031 (US$ Million)
  43. China Cancer Gene Therapy Market, by End-user, 2021-2031 (US$ Million)
  44. Japan Cancer Gene Therapy Market, by Therapy Type, 2021-2031 (US$ Million) 
  45. Japan Cancer Gene Therapy Market, by Indication , 2021-2031 (US$ Million)
  46. Japan Cancer Gene Therapy Market, by End-user, 2021-2031 (US$ Million)
  47. India Cancer Gene Therapy Market, by Therapy Type, 2021-2031 (US$ Million) 
  48. India Cancer Gene Therapy Market, by Indication , 2021-2031 (US$ Million) 
  49. India Cancer Gene Therapy Market, by End-user, 2021-2031 (US$ Million)
  50. South Korea Cancer Gene Therapy Market, by Therapy Type, 2021-2031 (US$ Million) 
  51. South Korea Cancer Gene Therapy Market, by Indication , 2021-2031 (US$ Million)
  52. South Korea Cancer Gene Therapy Market, by End-user, 2021-2031 (US$ Million)
  53. Australia Cancer Gene Therapy Market, by Therapy Type, 2021-2031 (US$ Million) 
  54. Australia Cancer Gene Therapy Market, by Indication , 2021-2031 (US$ Million)
  55. Australia Cancer Gene Therapy Market, by End-user, 2021-2031 (US$ Million)
  56. Rest of Asia Pacific Cancer Gene Therapy Market, by Therapy Type, 2021-2031 (US$ Million) 
  57. Rest of Asia Pacific Cancer Gene Therapy Market, by Indication , 2021-2031 (US$ Million)
  58. Rest of Asia Pacific Cancer Gene Therapy Market, by End-user, 2021-2031 (US$ Million)
  59. Latin America Cancer Gene Therapy Market, by Therapy Type, 2021-2031 (US$ Million) 
  60. Latin America Cancer Gene Therapy Market, by Indication , 2021-2031 (US$ Million)
  61. Latin America Cancer Gene Therapy Market, by End-user, 2021-2031 (US$ Million)
  62. Latin America Cancer Gene Therapy Market, by Country, 2021-2031 (US$ Million)
  63. Brazil Cancer Gene Therapy Market, by Therapy Type, 2021-2031 (US$ Million) 
  64. Brazil Cancer Gene Therapy Market, by Indication , 2021-2031 (US$ Million)
  65. Brazil Cancer Gene Therapy Market, by End-user, 2021-2031 (US$ Million)
  66. Mexico Cancer Gene Therapy Market, by Therapy Type, 2021-2031 (US$ Million) 
  67. Mexico Cancer Gene Therapy Market, by Indication , 2021-2031 (US$ Million)
  68. Mexico Cancer Gene Therapy Market, by End-user, 2021-2031 (US$ Million)
  69. Argentina Cancer Gene Therapy Market, by Therapy Type, 2021-2031 (US$ Million) 
  70. Argentina Cancer Gene Therapy Market, by Indication , 2021-2031 (US$ Million)
  71. Argentina Cancer Gene Therapy Market, by End-user, 2021-2031 (US$ Million)
  72. Rest of Latin America Cancer Gene Therapy Market, by Therapy Type, 2021-2031 (US$ Million) 
  73. Rest of Latin America Cancer Gene Therapy Market, by Indication , 2021-2031 (US$ Million)
  74. Rest of Latin America Cancer Gene Therapy Market, by End-user, 2021-2031 (US$ Million)
  75. Middle East & Africa Cancer Gene Therapy Market, by Therapy Type, 2021-2031 (US$ Million) 
  76. Middle East & Africa Cancer Gene Therapy Market, by Indication , 2021-2031 (US$ Million)
  77. Middle East and Africa Cancer Gene Therapy Market, by End-user, 2021-2031 (US$ Million)
  78. Middle East and Africa Cancer Gene Therapy Market, by Country/Region, 2021-2031 (US$ Million)
  79. GCC Countries Cancer Gene Therapy Market, by Therapy Type, 2021-2031 (US$ Million) 
  80. GCC Countries Cancer Gene Therapy Market, by Indication , 2021-2031 (US$ Million)
  81. GCC Countries Cancer Gene Therapy Market, by End-user, 2021-2031 (US$ Million)
  82. South Africa Cancer Gene Therapy Market, by Therapy Type, 2021-2031 (US$ Million) 
  83. South Africa Cancer Gene Therapy Market, by Indication , 2021-2031 (US$ Million)
  84. South Africa Cancer Gene Therapy Market, by End-user, 2021-2031 (US$ Million)
  85. Rest of Middle East and Africa Cancer Gene Therapy Market, by Therapy Type, 2021-2031 (US$ Million) 
  86. Rest of Middle East and Africa Cancer Gene Therapy Market, by Indication , 2021-2031 (US$ Million)
  87. Rest of Middle East and Africa Cancer Gene Therapy Market, by End-user, 2021-2031 (US$ Million)

List of Figures

 

  1. Cancer Gene Therapy Market Ecosystem  
  2. Snapshot of Global Cancer Gene Therapy Market, 2021-2031 
  3. Snapshot of Global Cancer Gene Therapy Market, By Region, 2021-2031 
  4. Global Cancer Gene Therapy Market: COVID-19 Pandemic Impact Assessment 
  5. Global Cancer Gene Therapy Market: Key Players & Competitive Positioning (2022) 
  6. Cancer Gene Therapy: Market Dynamics 
  7. Global Cancer Gene Therapy Market for Gene-Induced Immunotherapy, 2021-2031 (US$ Million) 
  8. Global Cancer Gene Therapy Market for Gene Transfer, 2021-2031 (US$ Million) 
  9. Global Cancer Gene Therapy Market for Oncolytic Virotherapy, 2021-2031 (US$ Million) 
  10. Global Cancer Gene Therapy Market for Lung Cancer, 2021-2031 (US$ Million) 
  11. Global Cancer Gene Therapy Market for Prostate Cancer, 2021-2031 (US$ Million) 
  12. Global Cancer Gene Therapy Market for Breast Cancer, 2021-2031 (US$ Million) 
  13. Global Cancer Gene Therapy Market for Pancreatic Cancer, 2021-2031 (US$ Million) 
  14. Global Cancer Gene Therapy Market for Other Indications, 2021-2031 (US$ Million)
  15. Global Cancer Gene Therapy Market for Academic & Research Institutes, 2021-2031 (US$ Million)
  16. Global Cancer Gene Therapy Market for Biopharmaceutical Companies, 2021-2031 (US$ Million)
  17. Global Cancer Gene Therapy Market for Others, 2021-2031 (US$ Million)
  18. U.S. Cancer Gene Therapy Market, 2021-2031 (US$ Million) 
  19. Canada Cancer Gene Therapy Market, 2021-2031 (US$ Million) 
  20. Germany Cancer Gene Therapy Market, 2021-2031 (US$ Million) 
  21. U.K. Cancer Gene Therapy Market, 2021-2031 (US$ Million) 
  22. France Cancer Gene Therapy Market, 2021-2031 (US$ Million) 
  23. Italy Cancer Gene Therapy Market, 2021-2031 (US$ Million) 
  24. Spain Cancer Gene Therapy Market, 2021-2031 (US$ Million) 
  25. Rest of Europe Cancer Gene Therapy Market, 2021-2031 (US$ Million) 
  26. China Cancer Gene Therapy Market, 2021-2031 (US$ Million) 
  27. Japan Cancer Gene Therapy Market, 2021-2031 (US$ Million) 
  28. India Cancer Gene Therapy Market, 2021-2031 (US$ Million) 
  29. South Korea Cancer Gene Therapy Market, 2021-2031 (US$ Million) 
  30. Australia Cancer Gene Therapy Market, 2021-2031 (US$ Million) 
  31. Rest of Asia Pacific Cancer Gene Therapy Market, 2021-2031 (US$ Million) 
  32. Brazil Cancer Gene Therapy Market, 2021-2031 (US$ Million) 
  33. Mexico Cancer Gene Therapy Market, 2021-2031 (US$ Million) 
  34. Argentina Cancer Gene Therapy Market, 2021-2031 (US$ Million) 
  35. Rest of Latin America Cancer Gene Therapy Market, 2021-2031 (US$ Million) 
  36. GCC Countries Cancer Gene Therapy Market, 2021-2031 (US$ Million) 
  37. South Africa Cancer Gene Therapy Market, 2021-2031 (US$ Million) 
  38. Rest of Middle East & Africa Cancer Gene Therapy Market, 2021-2031 (US$ Million) 
  39. GlaxoSmithKline Plc Revenue from 2019 Onwards (US$ Million)
  40. Merck & Co., Inc. Revenue from 2019 Onwards (US$ Million)
  41. GenVec Revenue from 2019 Onwards (US$ Million)
  42. Introgen Therapeutics Inc. Revenue from 2019 Onwards (US$ Million)
  43. Altor Bioscience Inc. Revenue from 2019 Onwards (US$ Million)
  44. BioCancell Therpeutic Inc. Revenue from 2019 Onwards (US$ Million)
  45. Bluebird bio-Inc. Revenue from 2019 Onwards (US$ Million)
  46. Bristol-Myers Squibb Company Revenue from 2019 Onwards (US$ Million)
  47. Abeona Therapeutics Inc. Revenue from 2019 Onwards (US$ Million)
  48. Asklepios BioPharmaceutical Inc. Revenue from 2019 Onwards (US$ Million)

Single User License
Single User License
Multi User License
Enterprise User License
$4,750.00
Provides access to one user only and should not be shared with other employees within the organization.
Provides access to up to five users within the department or an organization.
Provides access to all the employees in the organization. The report can also be shared with subsidiaries, sister concerns and group entities.
Grants user/users’ access to quantitative data only, which includes but is not restricted to numeric data, tables, and charts as defined by Growth+ Reports.
  • What are the significant driving and restraining factors for the Cancer Gene Therapy Market?
  • Who are the leading companies in the market?
  • Where can you find the updates on recent developments by market players?
  • When is the right time to get discounts on complete market reports?
  • Why to invest in the Cancer Gene Therapy Market?
  • How to improve your organizational performance?
  • How to shift customers towards your brand?

Recommended Reports